Home > Insider Trading > Filing (0001415889-24-000608)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1730430	Kiniksa Pharmaceuticals Ltd.	KNSA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1464583	R Michael Megna	C/O Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton D0 HM 11	Chief Accounting Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Common Share	Acquisiton	2024-01-02	16,670	$13.88	33,675	No	4	M	Direct
Class A Common Share	Disposition	2024-01-02	16,670	$19.17	17,005	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Share	Share Option	Disposition	2024-01-02	16,670	$0.00	16,670	$13.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,014		2028-08-05	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.13 to $19.43. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
This option is fully vested and exercisable.